PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels ...Middle East

PITTSBURGH, Dec. 3, 2020 /PRNewswire/ -- PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™ (lumasiran). The drug has been approved by the U.S....

Hence then, the article about pantherx rare pharmacy chosen as partner by alnylam pharmaceuticals for oxlumo lumasiran for the treatment of primary hyperoxaluria type 1 ph1 to lower urinary oxalate levels was published today ( Thursday 03/12/2020 - 10:15 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels )

Also on site :

• One of the 'Best Country Love Song Duets' Gets Reimagined as 'Incredibly Sad' Version by Kelly Clarkson
• Cómo la táctica de Israel de eliminar a los líderes iraníes podría complicar la búsqueda de Trump de una solución definitiva
• Ukraine-Russia war latest: Putin’s aide says no part of Russia is safe after Kyiv hits base 800km from border